0 items

in your cart

Prescription Drug Search

Product Request Form

Ofatumumab is currently not available.

Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Ofatumumab becomes available, please fill out the form below.


*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!

Search for a drug:


Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about ExpressMedsCanada.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Ofatumumab:

  • Algeria
  • Argentina
  • Aruba
  • Australia
  • Bermuda
  • Bosnia and Herzegovina
  • Cook Islands
  • Croatia
  • Cuba
  • Denmark
  • Estonia
  • European Union
  • Germany
  • Guatemala
  • Hong Kong
  • Iceland
  • India
  • Iraq
  • Liechtenstein
  • Malta
  • Netherlands Antilles
  • Norway
  • Paraguay
  • Philippines
  • Poland
  • Portugal
  • Qatar
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovenia
  • Spain
  • Sri Lanka
  • Switzerland
  • Trinidad and Tobago
  • Ukraine
  • United Arab Emirates
  • United Kingdom, UK
  • United States, US
  • Uzbekistan
View All Countries

Latest news releases on Ofatumumab:

Genmab Announces Financial Results for the First Quarter 2012 - msnbc.com

Arzerra(r) net sales increased 32% over Q1 2011 New Drug Application for ofatumumab submitted in Japan Amended protocol for ofatumumab Phase III head to head study vs rituximab in DLBCL; moved estimated primary data readout forward Improved ...

Genmab A/S : Daratumumab Clinical Data to Be Presented at ASCO and EHA - 4-traders (press release)

In addition, several other ofatumumab and daratumumab abstracts will be presented at the ASCO and EHA conferences. Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL - Abstract #6584 Poster presentation June 4 at 1:15PM ...

MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO Meeting - Market Wire

The issuer is solely responsible for the content of this announcement. Synergistic Effects Seen with Four Approved Treatment Options Including Rituximab and Ofatumumab MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced promising pre ...

DGAP-Adhoc: Milestone Triggered in Connection with Filing of New Drug Application in Japan for Arz - aktien-meldungen.de

The NDA is for Arzerra(r) (ofatumumab) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy. Today's announcement does not affect Genmab's financial guidance for 2012. About Genmab A S Genmab is a publicly ...

Milestone Triggered in Connection With Filing of New Drug Application in Japan for Arzerra - MENAFN

Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(R)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated ...

PRESS RELEASE: MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO Meeting - ad-hoc-news.de

approved therapeutic agents including the small-molecule drugs bendamustine (Ribomustin(®)) and fludarabine (Fludara(®)) as well as the anti-CD20 antibodies rituximab (Rituxan(®)) and ofatumumab (Arzerra(®)) were evaluated for their ability to enhance ...

Blood Cancers: What to Look for in Leukemia - Medscape News

The final abstract [6] I am going to mention involves the same agent but in combination with the anti-CD20 ofatumumab in relapse-refractory CLL. In a small number of patients treated with this combination, the response rate was 100%, including a number of ...

Pharmacyclics Reports Oral Presentations, Clinical Update Of Ibrutinib At ASCO - RTT News

The update on data presented for the first time would specifically include safety and efficacy data from the phase II CLL single agent trial in treatment-naive patients; safety and efficacy data from the phase Ib/II CLL combination trial with ofatumumab in ...

Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual … - Yahoo Finance

Byrd et al., The Ohio State University, Columbus, Ohio. Abstract # 6508: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma ...

United States: GSK And Genentech Settle Cabilly Patent Lawsuit - Mondaq

In the lawsuit, started in October 2009, GSK had sought a declaration that the Cabilly II / III patents were invalid, unenforceable and not infringed by the manufacture, use, sale, offer to sell or importation of GSK's ofatumumab (ARZERRA) antibody product.

Customer Service
1-866-799-3435 - Use Discount Code 7500 | Contact Form
Copyright © 2012 ExpressMedsCanada.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK